v3.22.2.2
Goodwill and Intangible Assets
 9 Months Ended
Oct. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS
Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):

December 31,
2021		Business acquisitionsCurrency translation adjustmentsOctober 1,
2022
CSCA(1)
$1,902.4 $93.3 $0.5 $1,996.2 
CSCI(2)
1,097.0 524.8 (189.1)1,432.7 
Total goodwill$2,999.4 $618.1 $(188.6)$3,428.9 

(1) We had no accumulated goodwill impairments as of October 1, 2022 and $6.1 million as of December 31, 2021.
(2) We had accumulated goodwill impairments of $878.4 million as of October 1, 2022 and as of December 31, 2021.

Intangible Assets

Intangible assets and related accumulated amortization consisted of the following (in millions):
 October 1, 2022December 31, 2021
 GrossAccumulated
Amortization		GrossAccumulated
Amortization
Indefinite-lived intangibles:
Trademarks, trade names, and brands$3.0 $— $3.5 $— 
In-process research and development60.5 — 1.8 — 
Total indefinite-lived intangibles$63.5 $— $5.3 $— 
Definite-lived intangibles:
Distribution and license agreements and supply agreements$78.1 $54.9 $73.2 $56.9 
Developed product technology, formulations, and product rights452.4 202.4 300.2 191.4 
Customer relationships and distribution networks1,717.0 876.3 1,820.7 887.8 
Trademarks, trade names, and brands2,304.5 415.5 1,482.3 394.2 
Non-compete agreements2.0 2.0 2.1 2.1 
Total definite-lived intangibles$4,554.0 $1,551.1 $3,678.5 $1,532.4 
Total intangible assets$4,617.5 $1,551.1 $3,683.8 $1,532.4 

We recorded amortization expense of $67.9 million and $178.8 million for the three and nine months ended October 1, 2022, respectively, and $52.2 million and $159.0 million for the three and nine months ended October 2, 2021, respectively.
On March 17, 2022, we announced that we received final approval from the U.S. Food and Drug Administration for the over-the-counter use of Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg). The approval triggered a $10.0 million milestone payment to the licensor, which was made in the second quarter of 2022 and capitalized as a definite-lived intangible asset.